Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data
[ad_1] A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. Jim Vondruska | Reuters Novo Nordisk‘s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial – a landmark finding that could put…